Stereotactic radiotherapy for oligometastases in the lymph nodes.
BED
hypofractionation
local control
lymph node metastases
oligometastasis
organ motion
radiosurgery
stereotactic radiotherapy
toxicity
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
09
2021
accepted:
27
12
2021
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
12
4
2022
Statut:
epublish
Résumé
Even though systemic therapy is standard treatment for lymph node metastases, metastasis-directed stereotactic radiotherapy (SRT ) seems to be a valid option in oligometastatic patients with a low disease burden. Positron emission tomography-computed tomography (PET-CT ) is the gold standard for assessing metastases to the lymph nodes; co-registration of PET-CT images and planning CT images are the basis for gross tumor volume (GTV ) delineation. Appropriate techniques are needed to overcome target motion. SRT schedules depend on the irradiation site, target volume and dose constraints to the organs at risk (OARs) of toxicity. Although several fractionation schemes were reported, total doses of 48-60 Gy in 4-8 fractions were proposed for mediastinal lymph node SRT, with the spinal cord, esophagus, heart and proximal bronchial tree being the dose limiting OAR s. Total doses ranged from 30 to 45 Gy, with daily fractions of 7-12 Gy for abdominal lymph nodes, with dose limiting OARs being the liver, kidneys, bowel and bladder. SRT on lymph node metastases is safe; late side effects, particularly severe, are rare.
Identifiants
pubmed: 35402021
doi: 10.5603/RPOR.a2022.0007
pii: rpor-27-1-46
pmc: PMC8989441
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
46-51Informations de copyright
© 2022 Greater Poland Cancer Centre.
Déclaration de conflit d'intérêts
Conflicts of interest The authors have no conflict of interest to declare.
Références
Strahlenther Onkol. 2015 Apr;191(4):310-20
pubmed: 25326142
Semin Radiat Oncol. 2016 Apr;26(2):112-9
pubmed: 27000507
Eur Urol Oncol. 2021 Apr;4(2):305-309
pubmed: 31558422
Radiother Oncol. 2018 Jan;126(1):177-180
pubmed: 28943046
Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e115-20
pubmed: 27133946
Oncologist. 2020 Feb;25(2):e311-e320
pubmed: 32043791
JAMA Oncol. 2020 May 1;6(5):650-659
pubmed: 32215577
Oncotarget. 2016 Aug 16;7(33):53321-53329
pubmed: 27462869
J Clin Oncol. 2018 Mar 1;36(7):710-719
pubmed: 29106810
Cancer Treat Rev. 2019 Feb;73:84-90
pubmed: 30684842
Radiat Oncol. 2016 Jan 22;11:9
pubmed: 26796633
Eur J Surg Oncol. 2020 May;46(5):883-887
pubmed: 31784203
BJU Int. 2017 Mar;119(3):406-413
pubmed: 27104782
Lancet Oncol. 2013 Jan;14(1):e28-37
pubmed: 23276369
Clin Exp Metastasis. 2021 Feb;38(1):11-29
pubmed: 33452954
Cancer Invest. 2017 Oct 21;35(9):586-593
pubmed: 28980836
Radiat Oncol. 2019 Nov 14;14(1):205
pubmed: 31727093
J Clin Oncol. 2018 Feb 10;36(5):446-453
pubmed: 29240541
Radiat Oncol. 2011 May 01;6:44
pubmed: 21529377
Eur Urol Focus. 2017 Dec;3(6):538-544
pubmed: 28801240
Anticancer Res. 2015 Sep;35(9):5103-10
pubmed: 26254414
Eur Urol. 2020 Apr;77(4):403-417
pubmed: 30773328
World J Urol. 2017 Jan;35(1):45-49
pubmed: 27233779
World J Urol. 2019 Dec;37(12):2623-2629
pubmed: 30191396
Oncotarget. 2015 Jun 20;6(17):15690-703
pubmed: 25881546
J Oral Maxillofac Surg. 2014 Nov;72(11):2319-32
pubmed: 25438279
J Nucl Med. 2015 Aug;56(8):1185-90
pubmed: 26112024
PLoS One. 2011;6(12):e28650
pubmed: 22174856
World J Urol. 2015 Aug;33(8):1197-203
pubmed: 25342516
Cancer. 2012 Jun 1;118(11):2962-70
pubmed: 22020702
J Clin Oncol. 1995 Jan;13(1):8-10
pubmed: 7799047
Clin Transl Oncol. 2021 Aug;23(8):1577-1584
pubmed: 33495981
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):55-69
pubmed: 26450693
J Natl Compr Canc Netw. 2012 Dec 1;10(12):1514-20
pubmed: 23221789
Clin Oncol (R Coll Radiol). 2018 Jan;30(1):5-14
pubmed: 29033164
Eur Urol Oncol. 2021 Jun;4(3):447-455
pubmed: 32536574
Lancet. 2019 May 18;393(10185):2051-2058
pubmed: 30982687
Med Phys. 2010 Aug;37(8):4078-101
pubmed: 20879569
Science. 2016 Apr 8;352(6282):169-75
pubmed: 27124450
BMC Cancer. 2019 Aug 19;19(1):816
pubmed: 31426760
Eur J Cancer. 2019 Nov;122:109-114
pubmed: 31671363
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):831-8
pubmed: 20800375
Radiother Oncol. 2017 Jul;124(1):1-10
pubmed: 28666551
Clin Oncol (R Coll Radiol). 2016 Jan;28(1):13-20
pubmed: 26385822
Clin Genitourin Cancer. 2017 Aug;15(4):e623-e632
pubmed: 28185875
Gynecol Obstet Invest. 2017;82(3):209-222
pubmed: 28183074